Marcaine with Epinephrine

Bupivacaine Hydrochloride And Epinephrine Bitartrate · BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL; EPINEPHRINE BITARTRATE .0091 mg/mL · Injection, Solution · Epidural; Infiltration; Intracaudal; Perineural · Hospira, Inc.

NDC 00409-1746-10 · 10 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →

The short version

5 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “delay in shipping of the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$67.21

Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$14,952

648 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Hospira, Inc.United States
analysis · label · manufacture · pack

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: NDA016964
TE code: AP
Approval date: Jan 1, 1982
Patents / exclusivity: None on file

Shortage history

In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)Feb 20, 2018
Delay in shipping of the drug
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months
In shortage now — Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)Feb 20, 2018
month 103 — 5× the typical 20-month injectable shortage · model puts 21% odds it resolves within 6 months

Recalls (this NDC)

Class II · TerminatedSep 16, 2016
Hospira Inc., A Pfizer Company — Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it to be less than the labeled potency.
Class II · TerminatedSep 16, 2016
Hospira Inc., A Pfizer Company — Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it to be less than the labeled potency.
Class I · TerminatedJun 17, 2014
Hospira Inc. — Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.
Class I · TerminatedApr 21, 2014
Hospira Inc. — Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.
Class I · TerminatedOct 18, 2013
Hospira Inc. — Presence of Particulate Matter: Units of this lot may have visible metal particles embedded in the vial and in the solution causing the product to be discolored.

Manufacturers of Bupivacaine Hydrochloride And Epinephrine Bitartrate (Injection, Solution)

Labeler	Strength	First seen	Last seen
Fresenius Kabi USA, LLC	BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mL	Jul 15, 2026	Sep 3, 2026
Hospira, Inc.	BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL; EPINEPHRINE BITARTRATE .0091 mg/mL	Jul 15, 2026	Sep 3, 2026
Septodont, Inc.	BUPIVACAINE HYDROCHLORIDE ANHYDROUS 5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mL	Jul 15, 2026	Sep 3, 2026
Sportpharm LLC	BUPIVACAINE HYDROCHLORIDE 5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mL	Sep 3, 2026	Sep 3, 2026
Fresenius Kabi USA, LLC	BUPIVACAINE HYDROCHLORIDE 7.5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mL	Jul 15, 2026	Sep 2, 2026
Henry Schein, Inc.	BUPIVACAINE HYDROCHLORIDE 2.5 mg/mL; EPINEPHRINE BITARTRATE .0091 mg/mL	Jul 15, 2026	Sep 2, 2026
Fresenius Kabi USA, LLC	BUPIVACAINE HYDROCHLORIDE 5 mg/mL; EPINEPHRINE BITARTRATE .005 mg/mL	Jul 15, 2026	Aug 31, 2026
Hospira, Inc.	BUPIVACAINE HYDROCHLORIDE 5 mg/mL; EPINEPHRINE BITARTRATE .0091 mg/mL	Jul 15, 2026	Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Marcaine with Epinephrine — NDC 00409-1746-10," retrieved September 3, 2026, https://drugdashboards.com/drug/00409174610.

Free to cite with attribution — see how the data is put together.